Metabolic Diseases

Metabolic diseases affect millions of sufferers worldwide and are having an increasingly negative impact upon the health of our society as a whole. Diabetes affects approximately 246 million people worldwide and is increasing; the IDF predicts 380 million diabetics by 2025. The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and the market is still expanding rapidly due to the high prevalence of diabetes and lifestyle changes. According to recent figures, type II diabetes affects more than 90% of diabetic people whilst those meeting the criteria set for obesity reaches 300 million respectively.

The SMi Group would like to announce its 2nd Metabolic Diseases Conference designed specifically to uncover the latest market trends, challenges and emerging therapies.

Take a closer look at key disease specific drugs on track towards regulatory approval and market release. Learn how to overcome challenges in developing novel metabolic therapies and discover what is really expected in a new product application and how to achieve it.

<><><><><><><><>Our exceptional Speaker line-up includes:

	Dr Michael Mark, Vice President, Metabolic Diseases Research, Boehringer Ingelheim
	Dr Michael R. Hanley, Vice President of Discovery Research, Amylin Pharmaceuticals
	Dr Douglas Greene, Chief Medical Officer, Sanofi-Aventis
	Professor Jon Arch, Professional Research Fellow and Deputy Director, Metabolic Research, University of Buckingham and former Director, Drug Discovery, GlaxoSmithKline
	Dr Michael Trautman, Medical Fellow, Clinical Investigations, Eli Lilly
	Dr Brian Hubbard, Senior Director, Atherosclerosis, Merck
	Dr John H, Johnson, Senior Director, Worldwide Business Development, Pfizer
	Professor David Heal, Director, Renasci
	Dr Johannes Zanzinger, Director, Global Licensing Metabolic Diseases, Boehringer Ingelheim
	Dr Timothy Herpin, Director, Metabolic Disease Licensing, Bristol-Myers Squibb
	Dr Manfred Ganz, Associate Professor of Clinical Management , Campus Biomedico, University of Rome, Italy

• Dr Uwe Gudat, Global Brand Medical Director, Dyslipidemia & Diabetes, Novartis
• Dr Tomas Landh, Director, Novo Nordisk
• Dr  Alexei Kharitonenkov, BioTechnology Discovery Research, Eli Lilly
• Dr Shankari Mylvaganam, Vice President of Research, Sapient Discovery
• Dr Farzaad Abdi-Dezfuli, Partner, Sarsia Seed Management AS
• Dr Eric Tomlinson, President & Chief Executive Officer, Altea Therapeutics Corporation
• Dr Mike Cawthorne, Director of Metabolic Research, University of Buckingham

This year’s conference cover:

• Emerging therapeutics in the metabolic disease market
• The future of drug discovery for metabolic diseases
• Current and future targets for next generation drugs in order for treating diabetes and obesity
• Regulatory developments and the licensing landscape
• Patient adherence issues and solutions
• Translational medicine
• Many metabolic links to symptomatic and pathophysiological manifestations of AD
• Kinase inhibitors in the treatment of metabolic diseases
• Fatty acids and fatty acid receptors
• Obesity as an inflammatory disease: how to treat
• Comparing DPP4 inhibitors with GLP-1 mimetics
• Nonpeptide GLP-1 agonists
• New generations of PPARs